Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

51716 items
12:00 AM, Sep 28, 2000  |  BC Extra | Company News

Genta licenses antisense technology to Oasis

GNTA granted Oasis Biosciences (San Diego, Calif.) a non-exclusive license to its antisense patents for use in Oasis's high throughput target validation technology. The deal includes upfront payments plus royalties....
12:00 AM, Sep 28, 2000  |  BC Extra | Company News

ValiGen subscribes to Celera database

ValiGen (Newtown, Penn.) entered into a 5-year subscription to all of CRA's integrated database products, bioinformatics systems and other discovery tools....
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

Eos raises $27.5 million

Eos Biotechnology (South San Francisco, Calif.), a genomics, bioinformatics and drug discovery company, raised $27.5 million in a private placement. Investors included Affymetrix (AFFX); Biogen (BGEN); Medarex (MEDX); U.S. Bancorp Piper Jaffray; and Robertson Stephens....
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

BTG to sell rights issue

BTG (LSE:BGC) plans to raise up to 125.6 million ($183.1 million) in a 1-for-9 rights issue of up to 10.5 million shares at 1200p underwritten by CS First Boston. The company plans to use the...
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

Durect raises $84 million

Drug delivery company Durect (DRRX, Cupertino, Calif.) raised $84 million in an IPO of 7 million shares at $12. The offering, which has a 1.1 million-share overallotment, was underwritten by Morgan Stanley Dean Witter; Chase...
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

FibroGen raises $56.5 million

FibroGen (South San Francisco, Calif.) raised $56.5 million in a venture financing. Investors included Franklin Templeton Investments; American Express Financial Advisors; BioFund Ventures; Life Sciences Venture Fund; Hotung Ventures; IBJ Investments; ORIX; Asahi Life; and...
12:00 AM, Sep 28, 2000  |  BC Extra | Company News

Ribozyme repurchases compound rights from Eli Lilly

RZYM repurchased rights from LLY to its Heptazyme (LY466700) chemically synthesized ribozyme against hepatitis C virus (HCV) (see BioCentury, March 29, 1999). Earlier this month, RZYM reported preliminary results of a Phase I trial...
12:00 AM, Sep 28, 2000  |  BC Extra | Politics & Policy

VA still fails to protect research subjects

The U.S. Veterans Administration hospital network and affiliated university hospitals routinely fail to comply with regulations that are designed to safeguard human subjects who participate in medical experiments, according to a General Accounting Office investigation...
12:00 AM, Sep 28, 2000  |  BC Extra | Company News

Biovail receives FDA approval

The FDA granted final marketing approval for BVF's generic version of Procardia XL nifedipine, which is marketed by Pfizer (PFE, New York, N.Y.) to treat hypertension and angina. Partner Teva (TEVA) will launch the product...
12:00 AM, Sep 28, 2000  |  BC Extra | Clinical News

Zarix begins Phase III

Zarix (Berwyn, Penn.) began an international Phase III trial of its Thymitaq nolatrexed (AG337) to treat hepatocellular carcinoma. Zarix licensed Thymitaq from Agouron Pharmaceuticals (La Jolla, Calif.), a subsidiary of Pfizer (PFE). Agouron ceased Phase...

Pages